Management of varicella-zoster virus infections in children

Area of Science:

• Pediatrics
• Infectious Diseases
• Immunology

Background:

• Varicella-zoster virus (VZV) infections, commonly known as chickenpox, pose a significant health concern, particularly in pediatric populations.
• While VZV vaccination is being implemented, its impact on overall VZV incidence is expected to be gradual.
• Antiviral therapies play a critical role in managing VZV infections, especially in immunocompromised individuals.

Purpose of the Study:

• To evaluate the role and efficacy of antiviral therapy in the management of VZV infections in children.
• To assess the impact of aciclovir in reducing morbidity and mortality associated with VZV in immunocompromised children.
• To determine the utility of oral aciclovir for varicella management in healthy children and adolescents.

Main Methods:

• Review of clinical data on VZV infection treatment in pediatric patients.
• Analysis of the efficacy of aciclovir in both primary and recurrent VZV infections.
• Assessment of aciclovir's effectiveness in immunocompromised versus healthy pediatric populations.

Main Results:

• Aciclovir therapy has dramatically reduced morbidity and mortality in immunocompromised children with VZV infections.
• Oral aciclovir demonstrates significant efficacy in managing varicella in healthy children and adolescents.
• Antiviral treatment remains a vital component of clinical practice despite the introduction of VZV vaccines.

Conclusions:

• Aciclovir is an effective and valuable treatment for varicella in children, including healthy individuals and adolescents.
• Antiviral therapy remains essential for managing VZV infections, particularly in immunocompromised children, significantly reducing severe outcomes.
• The combination of vaccination and antiviral therapy provides a comprehensive approach to VZV infection control in pediatric populations.